Wells Fargo Upgrades GeneDx: Analysts See Strong Upside After Stock Drop
Wells Fargo upgrades GeneDx to Overweight, saying the recent stock decline looks excessive and growth opportunities could drive momentum into 2026.
/ 1659 items
#XY↓
Hims Pulls Copycat Wegovy Weight-Loss Pill After Federal Pressure
Hims & Hers Health stops selling its cheaper Wegovy copycat pill just two days after launch following FDA crackdown and Justice Department investigation into compounded weight-loss drugs.
FDA Cracks Down on Compounded GLP-1 Weight Loss Drugs
FDA plans to restrict non-approved compounded GLP-1 drugs sold by Hims & Hers and compounding pharmacies, citing safety concerns and misleading marketing practices.
Pfizer’s Chantix Move Seen as Positive Signal for Achieve Life Sciences
Analysts say Pfizer listing Chantix on TrumpRx may support Achieve Life Sciences and boost confidence in cytisinicline’s approval prospects.
Hims vs. Novo Nordisk: Why the Pharma Giant Might Avoid a Legal Fight
Hims is selling a $49 copycat of Novo Nordisk's $149 weight-loss pill, but legal experts say Novo may avoid court battles due to risks of setting dangerous precedents.
uniQure's Fabry Disease Gene Therapy Shows Promising Results in Early Trial
AMT-191 gene therapy demonstrates sustained enzyme activity increases in Fabry disease patients, with 6 of 11 stopping traditional infusion therapy.